Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue from product sales	$ 180	$ 200	$ 153
Cost of sales	2,312	7,501	7,804
Gross loss	(2,132)	(7,301)	(7,651)
Selling, general and administrative expenses	11,623	9,440	11,546
Research and development expenses	16,199	13,762	10,193
Operating loss	(29,954)	(30,503)	(29,390)
Other income (expense):
Warrant revaluation and other finance income (expense)	3,930	(1,053)	20,404
Derivative revaluation expense	0	0	(23)
Interest income (expense)	6	2	(1,017)
Loss on extinguishment of debt	0	0	(5,617)
Other income	368	0	0
Loss from continuing operations before income taxes	(25,650)	(31,554)	(15,643)
Deferred tax benefit	0	0	2,500
Loss from continuing operations	(25,650)	(31,554)	(13,143)
Loss from discontinued operations, net of tax	0	0	(11)
Gain on sale of discontinued operations, net of tax	0	0	467
Net loss	(25,650)	(31,554)	(12,687)
Net loss attributable to non-controlling interest	0	0	(24)
Net loss attributable to Fibrocell Science, Inc. common stockholders	$ (25,650)	$ (31,554)	$ (12,711)
Per Share Information:
Loss from continuing operations - basic	$ (0.63)	$ (1.06)	$ (1.47)
Gain on sale of discontinued operations, net of tax - basic	$ 0.00	$ 0.00	$ 0.05
Net loss per common share - basic	$ (0.63)	$ (1.06)	$ (1.42)
Loss from continuing operations - diluted	$ (0.70)	$ (1.12)	$ (2.65)
Gain on sale of discontinued operations, net of tax - diluted	$ 0.00	$ 0.00	$ 0.05
Net loss per common share - diluted	$ (0.70)	$ (1.12)	$ (2.60)
Weighted average number of common shares outstanding - Basic (in shares)	40,789,445	29,830,207	8,965,098
Weighted average number of common shares outstanding - Diluted (in shares)	40,969,399	30,196,616	9,147,060